Solstar Pharma

September 19, 2024

Solstar

Solstar Pharma has developed an siRNA platform technology using proprietary modified nucleic acid chemistry. Our modified nucleotides enhance the stability and optimize the mRNA target activity of our siRNAs. We are harnessing the power of siRNA to inhibit pathogen replication such as in coronavirus disease or block the production of cancer-causing proteins.

Industry news

Panagitos Prinos - Takis photo

Panagiotis Prinos appointed as Director of Réseau DePTAQ

December 19, 2024

AReNA attended FISQ

December 19, 2024

AReNA attends CASTL’s Open Door Day

November 15, 2024

Epitopea closes their $31 million pre-Series A financing.

October 21, 2024

Congratulations to the Nobel Prize winners in Medicine!

September 19, 2024

Congratulations to the 23 recipients of the D2R funding programs

The creation of training programs to meet the needs of the RNA therapeutics industry

The creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

A new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

Quebec Launches AReNA to Become a Global Leader in RNA Therapies

A group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec

The long-overlooked molecule that will define a generation of science